Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Protein-Tyrosine Kinases
  • Pyrazoles
  • Pyrimidines

abstract

  • Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).

publication date

  • July 10, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3772525

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1215637

PubMed ID

  • 23782158

Additional Document Info

start page

  • 32

end page

  • 42

volume

  • 369

number

  • 1